Syneos Health Promotes Jason Meggs to Chief Financial Officer
May 09 2018 - 5:18AM
Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions
organization combining a CRO (Contract Research Organization) and a
CCO (Contract Commercial Organization), today announced that Jason
Meggs has been promoted to the position of Chief Financial Officer
of the Company, effective May 6. Meggs has served as interim CFO of
Syneos Health since February 2018.
“With two decades of financial experience across
both public and private markets, and a deep understanding of the
biopharma industry and our clinical and commercial businesses, our
Executive search revealed that Jason was the clear choice to be our
Chief Financial Officer,” said Alistair Macdonald, Chief Executive
Officer of Syneos Health. “Jason’s performance as the Company’s
Interim CFO, and years of prior service in key finance and
operational roles at INC Research, have only further reinforced
that he is the most qualified candidate for the position. Jason and
I have worked together for several years, and I look forward to
continuing to collaborate with him, along with our shareholders and
analysts, as we guide Syneos Health to its next phase of
growth.”
Meggs joined INC Research, the legacy company of
Syneos Health before its merger with inVentiv Health, in 2014 and
held senior financial and operational leadership roles, including
Executive Vice President and CFO of the Commercial Solutions
segment, following the closing of the merger. He has experience in
M&A transactions, including merger-related integration
leadership roles, initial public offerings (IPOs), and significant
public accounting and audit experience gained in roles with
Quintiles (now IQVIA), Deloitte and Arthur Andersen.
Meggs has a Bachelor of Science in Business
Administration degree in Accounting from Western Carolina
University and is a Certified Public Accountant.
About Syneos HealthSyneos Health (Nasdaq:SYNH)
is the only fully integrated biopharmaceutical solutions
organization. The Company, including a Contract Research
Organization (CRO) and Contract Commercial Organization (CCO), is
purpose-built to accelerate customer performance to address modern
market realities. Created through the merger of two industry
leading companies – INC Research and inVentiv Health – Syneos
Health brings together more than 21,000 clinical and commercial
minds with the ability to support customers in more than 110
countries. The Company shares insights, uses the latest
technologies and applies advanced business practices to speed
customers’ delivery of important therapies to patients. To learn
more about how Syneos Health is shortening the distance
from lab to life® visit syneoshealth.com.
Contacts
Investor Relations:Ronnie SpeightVice President,
Investor RelationsPhone: +1 919 745 2745Email:
Investor.Relations@syneoshealth.com
Press/Media:Danielle DeForgeSenior Director,
External CommunicationsPhone: +1 781 425 2624Email:
danielle.deforge@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024